Description
LL-37 5mg – Cathelicidin Antimicrobial Research Peptide Australia
LL-37 5mg is a synthetic research peptide listed by Peps Aussie Australia for scientific investigation, laboratory analysis and controlled experimental research.
LL-37 is a 37-amino-acid peptide corresponding to a naturally occurring component of the human innate immune system. It is derived from the human cathelicidin precursor protein, commonly known as hCAP18, and has attracted scientific interest because of its involvement in antimicrobial defence, immune signalling and cellular responses to environmental challenges.
Published laboratory research has examined LL-37 in relation to bacterial membrane interactions, antimicrobial mechanisms, inflammatory signalling, epithelial biology and experimental wound-associated processes.
LL-37 is frequently described as a host defence peptide because its biological functions extend beyond direct antimicrobial activity to include interactions with immune cells and cellular signalling pathways.
However, antimicrobial activity observed in laboratory experiments does not establish that a research-grade LL-37 material is safe or effective for treating infections, improving wound healing or managing inflammatory conditions in humans.
Peps Aussie lists LL-37 in a nominal 5mg size for laboratory research and analytical applications.
Important: LL-37 5mg is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, topical application, administration, therapeutic use or clinical treatment.
What Is LL-37?
LL-37 is a 37-amino-acid cationic peptide belonging to the cathelicidin family of antimicrobial peptides.
In humans, LL-37 is generated through processing of the cathelicidin precursor protein hCAP18, encoded by the CAMP gene.
The name LL-37 reflects the two leucine residues at the beginning of its commonly described sequence and its length of 37 amino acids.
LL-37 is produced in association with several cell types and tissues involved in innate immune defence, including neutrophils and epithelial cells.
Its biological characteristics include:
- A positively charged molecular structure.
- Interactions with negatively charged biological membranes.
- Antimicrobial activity in certain experimental systems.
- Involvement in immune-cell signalling.
- Interactions with inflammatory pathways.
- Participation in epithelial and wound-associated biological processes.
LL-37 has also been investigated in relation to nucleic acid interactions and immune receptor signalling.
These properties make it an important subject of research in immunology, microbiology and molecular biology.
LL-37 and the Human Cathelicidin System
Cathelicidins are a family of host defence peptides found in numerous animal species.
Human LL-37 is the best-characterised mature peptide derived from the human cathelicidin precursor.
The cathelicidin system forms part of innate immunity, which provides early biological responses to microorganisms and other environmental challenges.
Research involving LL-37 contributes to understanding how host defence peptides interact with microbial structures, immune cells and surrounding tissues.
LL-37 Peptide Research and Scientific Applications
Published research has examined LL-37 across several areas of microbiology, immunology and cellular biology.
The following sections describe scientific research topics rather than proven biological or therapeutic effects of the Peps Aussie material.
1. Antimicrobial Peptide Research
One of the most widely investigated characteristics of LL-37 is its antimicrobial activity in experimental systems.
Laboratory studies have examined LL-37 interactions with different microorganisms, including certain bacterial and fungal species.
Relevant research topics include:
- Antimicrobial peptide mechanisms.
- Bacterial membrane interactions.
- Microbial susceptibility testing.
- Host defence peptide activity.
- Concentration-dependent experimental responses.
- Environmental effects on antimicrobial activity.
- Comparative antimicrobial peptide research.
LL-37 activity can vary considerably depending on the microorganism, experimental conditions, ionic strength and other factors.
Results from laboratory susceptibility studies do not establish clinical effectiveness against infections.
2. Bacterial Membrane Interaction Research
LL-37 has been investigated for its ability to interact with microbial membranes.
Its cationic and amphipathic properties contribute to research interest in peptide–membrane interactions.
Relevant scientific topics include:
- Electrostatic interactions with membranes.
- Lipid bilayer organisation.
- Membrane permeability.
- Peptide insertion into lipid environments.
- Experimental membrane disruption.
- Structure–activity relationships.
- Membrane selectivity.
These investigations contribute to understanding the molecular mechanisms of host defence peptides.
Membrane-associated activity may also be relevant to experimental assessments of peptide interactions with mammalian cells, including potential cytotoxic effects.
3. Innate Immune Signalling and Immunomodulation
LL-37 has been investigated as a molecule involved in immune signalling and cellular communication.
Research has examined its interactions with immune cells and inflammatory pathways.
Relevant topics include:
- Innate immune responses.
- Cytokine-associated signalling.
- Chemotactic responses.
- Immune-cell recruitment.
- Receptor-associated signalling.
- Host defence mechanisms.
- Inflammatory pathway regulation.
LL-37 can exhibit different effects depending on cell type, concentration and experimental conditions.
Its immunological activity should not be described as uniformly anti-inflammatory or immune-enhancing.
4. Wound-Associated Biology and Epithelial Research
LL-37 has been investigated in experimental models involving epithelial tissues and wound-associated cellular processes.
Epithelial cells form protective barriers and participate in tissue responses to injury.
Research topics include:
- Epithelial cell signalling.
- Cell migration in experimental models.
- Wound-associated molecular pathways.
- Tissue barrier biology.
- Cellular responses to injury.
- Interactions between host defence peptides and epithelial cells.
Some studies have explored LL-37-associated changes in cellular behaviour under controlled experimental conditions.
These findings do not establish that LL-37 safely accelerates wound healing in humans.
5. Inflammatory Pathways and Immune Regulation
LL-37 has a complex relationship with inflammatory biology.
Depending on the experimental context, LL-37 has been associated with both pro-inflammatory and inflammation-modulating responses.
Relevant research areas include:
- Cytokine signalling.
- Immune receptor activation.
- Inflammatory gene expression.
- Cellular stress responses.
- Host defence signalling.
- Interactions with inflammatory mediators.
The biological effects of LL-37 are highly context-dependent.
Consequently, laboratory findings should not be interpreted as evidence that LL-37 treats inflammatory or autoimmune diseases.
6. Biofilm and Microbial Community Research
Microbial biofilms are organised communities of microorganisms associated with surfaces and extracellular matrices.
LL-37 has been investigated in experimental studies involving microbial biofilm formation and behaviour.
Relevant topics include:
- Biofilm formation.
- Microbial surface interactions.
- Peptide effects on microbial communities.
- Biofilm-associated signalling.
- Experimental antimicrobial susceptibility.
- Environmental influences on peptide activity.
These studies contribute to understanding antimicrobial peptide interactions with complex microbial systems.
They do not establish that LL-37 is clinically effective against biofilm-associated infections.
7. Peptide Structure and Analytical Characterisation
LL-37 is also relevant to analytical investigations involving peptide structure, molecular identity and material quality.
Laboratories evaluating LL-37 may investigate:
- Confirmation of the declared peptide identity.
- Amino acid sequence verification.
- Molecular mass determination.
- Secondary structure under different conditions.
- Chromatographic purity profiles.
- Peptide-related impurities.
- Content determination.
- Material stability.
- Batch-to-batch analytical consistency.
Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) may be appropriate depending on the formulation and analytical objectives.
LL-37 5mg Research Peptide Specifications
Peps Aussie lists LL-37 in a nominal 5mg size.
| Specification | Details |
|---|---|
| Product name | LL-37 |
| Alternative designation | Human cathelicidin antimicrobial peptide |
| Listed size | 5mg |
| Peptide type | Cathelicidin-derived host defence peptide |
| Peptide length | 37 amino acids |
| Biological precursor | hCAP18 |
| Associated gene | CAMP |
| Research category | Immunology, microbiology and host defence peptide research |
| Research areas | Membrane interactions, antimicrobial mechanisms and immune signalling |
| Supplier | Peps Aussie Australia |
| Intended use | Laboratory research and analytical investigation only |
The scientific characteristics above describe LL-37 as discussed in published literature. They do not independently verify the identity, composition, purity or content of the supplied material.
Exact molecular identity, amino acid sequence, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.
LL-37 Certificate of Analysis (COA) and Quality Documentation
Analytical verification is an important consideration when evaluating synthetic research peptides.
Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.
View Peps Aussie Certificates of Analysis
When evaluating LL-37 analytical documentation, researchers should consider:
- Peptide identity: Whether testing supports the declared LL-37 identity.
- Sequence verification: Whether analytical evidence is consistent with the expected 37-amino-acid sequence.
- Purity assessment: Whether suitable methods were used to evaluate impurities.
- Content determination: Whether quantitative testing supports the declared material quantity.
- Batch traceability: Whether the certificate corresponds to the supplied production lot.
- Testing methodology: Whether the analytical techniques are appropriate for the peptide.
- Additional testing: Whether relevant contamination or other quality assessments were performed.
High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.
A certificate should be interpreted according to the tests actually performed.
The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage or independent verification of every production batch.
LL-37 Storage and Laboratory Handling
Research peptides require appropriate handling to support sample integrity and experimental reproducibility.
Storage requirements for LL-37 depend on the formulation, packaging and validated manufacturer stability information.
Laboratories should consider:
- Appropriate storage temperature.
- Protection from light and moisture where necessary.
- Suitable laboratory containers.
- Compatibility with analytical solvents.
- Stability following sample preparation.
- Potential degradation during storage.
- Appropriate laboratory handling and disposal procedures.
Because LL-37 can interact with biological membranes and other molecular components, laboratories should also consider possible adsorption, aggregation and matrix-dependent effects during analytical work.
No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.
All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.
LL-37 5mg Australia – Product Availability and Shipping
Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.
LL-37 5mg is the currently listed nominal product size.
Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.
For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.
Frequently Asked Questions About LL-37
What is LL-37?
LL-37 is a 37-amino-acid cathelicidin-derived peptide involved in the human innate immune system. It has been investigated in antimicrobial, immunological and cellular signalling research.
What is LL-37 studied for?
Published research has examined LL-37 in relation to microbial membrane interactions, antimicrobial activity, immune signalling, epithelial biology and experimental wound-associated processes.
Is LL-37 an antimicrobial peptide?
Yes. LL-37 is classified as a host defence peptide with antimicrobial activity demonstrated in certain laboratory systems. Its activity depends on the microorganism and experimental conditions.
What does LL-37 stand for?
The name refers to the two leucine residues at the beginning of its commonly described amino acid sequence and its length of 37 amino acids.
Is LL-37 involved in immune signalling?
LL-37 has been investigated for its interactions with immune cells, inflammatory mediators and cellular signalling pathways.
Does LL-37 help wounds heal?
Some preclinical research has examined LL-37 in wound-associated biological models. These findings do not establish that LL-37 is safe or effective for wound treatment in humans.
Can LL-37 treat bacterial infections?
No clinical treatment claim is made for this research material. Antimicrobial activity observed in laboratory studies does not establish clinical effectiveness or safety against bacterial infections.
What size does Peps Aussie list?
Peps Aussie lists LL-37 in a 5mg nominal size. Researchers should verify the product label and associated analytical documentation.
Does LL-37 have a Certificate of Analysis?
Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.
How should LL-37 be stored?
Storage requirements depend on the formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.
Is LL-37 approved for human or veterinary use?
No medical or veterinary approval is claimed for this research product. It is not supplied for human or animal consumption, topical application, administration, diagnosis, prevention or treatment.
LL-37 Research Peptides at Peps Aussie Australia
Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating immunology, microbiology and molecular biology.
LL-37 remains a subject of scientific interest because of its involvement in host defence mechanisms, membrane interactions and immune signalling.
Researchers evaluating LL-37 5mg should prioritise accurate peptide identification, suitable analytical documentation, batch traceability and validated laboratory procedures.
Explore the Peps Aussie research catalogue at pepsaussie.com.
Research Use Only Disclaimer
LL-37 5mg is intended strictly for laboratory research and analytical purposes only.
This product is not intended for human or animal consumption, injection, topical application, administration, therapeutic use or clinical treatment.
Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish antimicrobial treatment efficacy, wound-healing benefits, immune enhancement, clinical safety or therapeutic suitability for the material offered.
No dosing, self-administration or therapeutic guidance is provided.

Reviews
There are no reviews yet.